Targeting BCL 2 with venetoclax is a promising

Targeting BCL 2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL 2 rearrangements by Akiko Uchida, Yasushi Isobe, Junko Asano, Yu Uemura, Masahiro Hoshikawa, Masayuki Takagi, and Ikuo Miura haematol Volume 104(7): 1417 -1421 June 30, 2019 © 2019 by Ferrata Storti Foundation

Expression of MYC and BCL 2 family proteins in germinal center B-cell-like diffuse large

Characteristics of four germinal center B-cell-like diffuse large B-cell lymphoma-derived cell lines. Akiko Uchida

Growth inhibitory effect and apoptotic sensitivity of the four cell lines to JQ-1 and

Alteration of apoptotic sensitivity to venetoclax in combination with S 63845. Akiko Uchida et

Venetoclax leads to dephosphorylation of BCL 2 and downregulates MCL 1 expression in the two double-hit and double-protein-expression lymphoma cell lines. Akiko Uchida et al. Haematologica 2019; 104: 1417 -1421 © 2019 by Ferrata Storti Foundation

Treatment with venetoclax augments the binding of PP 2 A B 56α to BCL 2 in the double-hit and double-protein-expression lymphoma cells. Akiko Uchida et al. Haematologica 2019; 104: 1417 -1421 © 2019 by Ferrata Storti Foundation

A low concentration of venetoclax induces apoptosis in primary double-hit and double-proteinexpression lymphoma cells. Akiko Uchida et al. Haematologica 2019; 104: 1417 -1421 © 2019 by Ferrata Storti Foundation